Comparing different doses of magnesium for treating rapid atrial fibrillation
Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
PHASE3 · Wake Forest University Health Sciences · NCT06376916
This study is testing whether different doses of magnesium can help people with rapid atrial fibrillation feel better compared to a placebo.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 153 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences (other) |
| Locations | 1 site (Oak Lawn, Illinois) |
| Trial ID | NCT06376916 on ClinicalTrials.gov |
What this trial studies
This clinical trial is a prospective, randomized, double-blinded study aimed at evaluating the safety and efficacy of intravenous magnesium at two different doses (2g and 4g) compared to a placebo in patients experiencing atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). The study seeks to determine the optimal dosing of magnesium, which has been used as an adjunct therapy in managing cardiac arrhythmias. Participants will be monitored for their heart rates and overall response to the treatment, contributing to a better understanding of magnesium's role in this context.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have a primary diagnosis of AFF RVR with a heart rate of 120 bpm or greater.
Not a fit: Patients who are hemodynamically unstable, have acute heart failure, or are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help establish the most effective magnesium dosage for treating AFF RVR, potentially improving patient outcomes.
How similar studies have performed: While there has been limited research on optimal magnesium dosing for AFF RVR, this study builds on previous findings and aims to fill a gap in the existing literature.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years or older * Able to provide informed consent * Primary diagnosis AFF RVR greater than or equal to 120 bpm * Diltiazem as rate control agent * English speaking Exclusion Criteria: * Hemodynamically unstable patients (SBP \<90, MAP \<65) * Impaired consciousness * End stage renal disease on hemodialysis or peritoneal dialysis * Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging * Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis * Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response * Acute myocardial infarction * Pregnancy defined as a positive urine HCG (human chorionic gonadotropin) * Contraindications to magnesium sulfate (including myasthenia gravis) * Allergy or sensitivity to any study drugs * Previously enrolled in this trial during a different patient encounter * Withdrew from study
Where this trial is running
Oak Lawn, Illinois
- Advocate Christ Medical Center Emergency Department (ACMC ED) — Oak Lawn, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Travis Hase, MD — Wake Forest University Health Sciences
- Study coordinator: Marc McDowell, PharmD
- Email: marc.mcdowell@aah.org
- Phone: (708) 684-1078
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response